DRMA

Dermata Therapeutics Inc

Add to Watchlist

Advanced Chart

5.330

-0.08(-1.479%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

5.5606

Open

5.240

VWAP

5.33

Vol

6.81K

Mkt Cap

3.63M

Low

5.100

Amount

36.30K

EV/EBITDA(TTM)

Total Shares

562.18K

-2.79M

EV/OCF(TTM)

P/S(TTM)

Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, XYNGARI and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, XYNGARI, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 30 million patients seeking treatment. The Company’s second product candidate, DMT410, uses its XYNGARI product candidate as a new method for needle-free intradermal delivery of botulinum toxin for the treatment of multiple aesthetic applications and medical skin diseases.

1 Analyst Rating

-43.71% Downside

Wall Street analysts forecast DRMA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRMA is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

-43.71% Downside

Current: 5.330

Low

3.00

Averages

3.00

High

3.00

-43.71% Downside

Current: 5.330

Low

3.00

Averages

3.00

High

3.00

Maxim

Anthony Vendetti

Buy

downgrade

$6 -> $3

2025-05-21

Reason

Maxim

Anthony Vendetti

Price Target

$6 -> $3

2025-05-21

downgrade

Buy

Reason

Maxim analyst Anthony Vendetti lowered the firm's price target on Dermata Therapeutics to $3 from $6 and keeps a Buy rating on the shares. The firm notes the company's Q1 operating expenses were below its estimates while also citing its statistically significant positive topline data from STAR-1 study, though its adjusted model reflects Dermata's anticipated capital raise, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Dermata Therapeutics Inc (DRMA.O) is -0.44, compared to its 5-year average forward P/E of -0.69. For a more detailed relative valuation and DCF analysis to assess Dermata Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.69

Current PE

-0.44

Overvalued PE

-0.13

Undervalued PE

-1.24

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00